Clinical trial NCT06009627: Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients
Official title: Phase II Clinical Study of Darsilide Combined With Exemestane+Goserelin Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
PHASE3
Conditions: Breast Cancer
Lead sponsor: Tianjin Medical University Cancer Institute and Hospital
Sponsor class: OTHER
First posted: 2023-08-24
Enrollment: 119
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A multicenter, prospective, open, randomized cohort, non controlled phase II clinical study to evaluate the effectiveness and safety of Darxil combined with Exemestane+goserelin neoadjuvant endocrine therapy in HR positive and HER2 negative premenopausal breast cancer patients. The study object was to evaluate the HR positive and HER2 negative premenopausal breast cancer patients with SD after 2 cycles of neoadjuvant chemotherapy. The main endpoint was the objective response rate (ORR) of treatment

Detailed description: A multicenter, prospective, open, randomized cohort, non controlled phase II clinical study to evaluate the effectiveness and safety of Darxil combined with Exemestane+goserelin neoadjuvant endocrine therapy in HR positive and HER2 negative premenopausal breast cancer patients. The study object was to evaluate the HR positive and HER2 negative premenopausal breast cancer patients with SD after 2 cycles of neoadjuvant chemotherapy. The main endpoint was the objective response rate (ORR) of treatment。Objective: To evaluate the efficacy and safety of darsilide combined with endocrine therapy in SD patients with HR positive and HER2 negative premenopausal breast cancer after 2 cycles of neoadjuvant chemotherapy. It is planned to recruit 119 HR positive and HER2 negative premenopausal breast cancer patients in Group A to conduct the trial with Simon's two-stage design. The null hypothesis is a true response rate of 0.2, while the alternative hypothesis is a true response rate of 0.4. The experiment was conducted in two stages. In the first stage, 13 patients were enrolled. If there are ≤ 3 responses in 13 patients, the study will be stopped Early stopping. Otherwise, continue30 patients were enrolled, with a total sample size of 43. If there are ≥ 13 patients responding, the treatment is effective. Group B was randomly assigned in a 1:1 ratio, with the same number of participants as Group A, resulting in 43 final participants. Calculated based on the proportion of SD patients in 2 cycles of neoadjuvant chemotherapy accounting for 80%, and considering a 10% dropout rate, the final enrollment was made The sample size is 119 cases. The actual samples for molecular testing can be randomly selected based on clinical efficacy, with a statistically significant number.

Eligibility criteria: Inclusion Criteria:

* All patients were operable estrogen receptor (ER) positive (\>1%), regardless of PR expression level, HER2 receptor negative invasive breast cancer. Follow the 2018 ASCO-CAP HER2 negative interpretation guideline standard. Confirmed by the pathological laboratory that the immunohistochemical (IHC) score is 0 or 1-2+and the in situ hybridization (ISH) test is negative (ISH amplification rate\<2.0);
* Stage II-III initial treatment patients whose tumor staging meets the AJCC 8th edition standards;
* At least one measurable breast and/or axillary disease;
* ECOG 0-1, with an estimated lifespan of at least 12 months;
* The functional level of the main organs must meet the following requirements:

Blood routine: ANC ≥ 1.5 × ten9/L; PLT ≥ 90 × ten9/L; Hb ≥ 90 g/L;Blood biochemistry: TBIL ≤ 2.5 × ULN; ALT and AST ≤ 2.5 × ULN; BUN and Cr≤ 1.5 × ULN;

* Lead ECG: QT interval (QTcF) corrected by Fridericia method\<470 ms for women;
* Able to accept all puncture biopsies required by the protocol;
* Volunteer to join this study, sign informed consent, have good compliance, and be willing to cooperate with follow-up;
* Women with fertility potential must have a negative Pregnancy test (urine or serum) within 7 days after administration,

And agree to use acceptable birth control methods during the study period to avoid pregnancy.

Exclusion Criteria:

* Received any form of anti-tumor treatment within 28 days prior to the start of the study;
* Simultaneously receiving any anti-tumor treatment beyond the provisions of other protocols;
* Bilateral breast cancer, inflammatory breast cancer or occult breast;
* Stage IV breast cancer;
* Severe dysfunction of important organs such as heart, liver, and kidney;
* Unable to swallow, chronic diarrhea and Bowel obstruction, there are many factors that affect drug taking and absorption;
* Participated in other drug clinical trials within 4 weeks prior to enrollment;
* Those with a known history of allergies to the drug components of this protocol; Have a history of immunodeficiency, including positive Diagnosis of HIV/AIDS test Sex, HCV, active hepatitis B, or other acquired or congenital immunodeficiency diseases Illness or a history of organ transplantation;
* Have ever suffered from any heart disease, including: (1) arrhythmia that requires medication or has clinical significance

Primary outcomes:
measure: Objective response rate (ORR) for treatment
timeFrame: At the end of the second cycle (each cycle is 21 or 28 days)
Secondary outcomes:
measure: Tumor residual load
timeFrame: At the end of the 6 cycle (each cycle is 21 or 28 days)
Other outcomes:
measure: Breast retention rate
timeFrame: At the end of the 6 cycle (each cycle is 21 or 28 days)
measure: Event free lifetime
timeFrame: At the end of the 6 cycle (each cycle is 21 or 28 days)
measure: Overall survival (OS)
timeFrame: 2years
Locations:
city: Tianjin
country: China
facility: Jie Ge
state: Tianjin
Study officials:
affiliation: yes
name: jie 1 ge, 1
role: STUDY_DIRECTOR
References: